QualityStocks would like to highlight Cellceutix (OTCBB: CTIX), an emerging bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Their flagship compound, Kevetrin(TM), is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today's cancer therapies (drug-resistant cancers).
In the company’s news yesterday,
The U.S. Food and Drug Administration (FDA) recently approved Cellceutix’s Investigational New Drug (IND) application for Kevetrin™, the company’s novel anti-cancer compound. In addition, the biopharmaceutical company was notified that both the Institutional Review Board (IRB) and the Scientific Review Committee (SRC) have approved clinical trial protocol.
The noted FDA-approval authorizes the company to move forward with the phase 1 trial, which will be conducted at Harvard Cancer Center’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center.
“In many, if not the majority, of instances, approval from the IRB and SRC can take months to receive. For us to be notified the same day as the FDA clearance that the protocol has been approved by the hospital is extremely rare and I believe that shows the commitment to commence the human trials as quickly as possible,” Dr. Krishna Menon, chief scientific officer at Cellceutix stated in the press release. “Everything is coming together very nicely and we will now be meeting with the host hospitals regarding the scheduling of patient enrollment and the first doses of Kevetrin to be administered.”
Among stated objectives of the clinical trial, the company hopes to determine the pharmacokinetics, pharmacodynamics, tolerance, and maximum tolerated dose (MTD) of Kevetrin in patients with refractory solid tumors. To achieve these endpoints, Cellceutix will enroll and dose 40 patients in the dose escalation portion of the study.
Once the MTD is established, the company will enroll up to 12 additional patients at the MTD dose level to further evaluate this dosage safety and pharmacodynamics.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.